Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The progression of neurodegeneration is slowed by treatment with deacetylase inhibitors, further emphasizing the impor- tance of a controlled balance of protein acetylation and deacetylation in cellular functions in diverse tissues (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
In the citing paper
“A recent report showed that neurodegeneration triggered by expression of the polyglutamine-containing protein Httex1p involves inhibition of CBP/p300- and PCAF-AT activities (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
Citations
Cites
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
Brand, A. H., & Perrimon, N. (1993) · Development · doi:10.1242/dev.118.2.401 · Cited by 9,612
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 1×
“We found that even normal repeat Htt can bind to and inhibit acetyltransferase activity ( Figs 1 and 2 ), so why is pathology associated with only expanded repeat Htt? Mutant Htt can be proteolytically processed; the pathogenic fragment localizes to the nucleus, where it is capable of inhibiting acetyltransferase acti…”
BackgroundA p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479 · cited 1×
“, pGST–P/CAF-AT domain (encoding amino acids 87–768), and pcDNA3 containing the cDNA for P/CA”
MethodGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The aetiology of several other neurodegenerative diseases, including spinocerebellar ataxia I and Kennedy's disease, also involves expansion of a polyglutamine repea”
BackgroundHistone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,094
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062 · cited 1×
“We previously found that a fragment of mutant Htt interacts directly with CBP, which contains an acetyltransferase domain and is a co-activator of numerous promoter”
BackgroundSelf-citationLuo, L., Liao, Y. J., Jan, L. Y., & Jan, Y. N. (1994) · Genes & Development · doi:10.1101/gad.8.15.1787 · Cited by 983
Cited by
Items 701–800 of 1,000
Environmental stimulation in Huntington disease patients and animal models
Novati, A., Nguyen, H. P., & Schulze-Hentrich, J. M. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105725 · Cited by 32
Wang, L., Lin, F., Wang, J., Wu, J., Han, R., Zhu, L., Zhang, G., DiFiglia, M., & Qin, Z. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmr125 · Cited by 26
“Soluble mhtt could also interact with both the glutamine-rich activation domain and the acetyl transferase domain of CBP, which led to the reduction in the acetyl-transferase activity of CBP and caused a reduction in histone acetylation [38].”
BackgroundDegradation of Misfolded Proteins by Autophagy: Is it a Strategy for Huntington's Disease Treatment?
Lin, F., & Qin, Z. (2013) · Journal of Huntington s Disease · doi:10.3233/jhd-130052 · Cited by 30
“Steffan et al. demonstrated that mutant Htt interacts directly with the histone acetyltransferase (HAT) domain of CREB binding protein (CBP) [55].”
Steffan, J. S., & Thompson, L. M. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.2.201 · Cited by 29
“In addition, HDACis can rescue polyQmediated pathogenesis in vivo in Drosophila, and toxicity in cell culture [45,47].”
BackgroundMethodInfluentialSelf-citationNuclear localization of N‐terminal mutant huntingtin is cell cycle dependent
Martín-Aparicio, E., Ávila, J., & Lucas, J. J. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02075.x · Cited by 26
“…in the nuclear : cytoplasmic ã 2002 Federation of European Neuroscience Societies, European Journal of Neuroscience, 16, 355±359 distribution of transfected htt can be found, even when short exon 1 truncated forms are expressed (Cooper et al., 1998; Hackam et al., 1998; Waelter et al., 2001).”
BackgroundZhang, Q., Chen, Z. S., An, Y., Liu, H., Hou, Y., Li, W., Lau, K., Koon, A. C., Ngo, J. C. K., & Chan, H. Y. E. (2018) · RNA · doi:10.1261/rna.062703.117 · Cited by 26
“In addition to in vitro models, we also investigated the inhibitory effect of TAT-BIND on neurodegeneration in flMJDQ27/84 (Zhang et al. 2016) and the Htt-exon1Q93 Drosophila (Steffan et al. 2001) in vivo.”
Newton, A. H., & Pask, A. J. (2020) · Communications Biology · doi:10.1038/s42003-020-01501-3 · Cited by 29
Basavarajappa, B. S., & Subbanna, S. (2024) · Epigenomics · doi:10.2217/epi-2023-0428 · Cited by 26
Recent Advances in Medicinal Chemistry of Histone Deacetylase Inhibitors
Weinmann, H., & Ottow, E. (2004) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(04)39015-9 · Cited by 25
Positioning the genome within the nucleus
Verschure, P. J. (2004) · Biology of the Cell · doi:10.1016/j.biolcel.2004.07.001 · Cited by 27
“…at pericentric heterochromatin, decoration of the inactive X chromosome, Polycomb and Trithorax mediated transcriptional memory and regulation of promoter activity at euchromatic positions (Strahl and Allis, 2000; Noma et al., 2001; Hall et al., 2002; Peters et al., 2003; Rice et al., 2003).”
BackgroundCavallo, F., Troglio, F., Fagà, G., Fancelli, D., Shyti, R., Trattaro, S., Zanella, M., D’Agostino, G. A., Hughes, J. M., Cera, M. R., et al. (2020) · Molecular Autism · doi:10.1186/s13229-020-00387-6 · Cited by 25
Fusco, F. R., Anzilotti, S., Giampà, C., Dato, C., Laurenti, D., Leuti, A., D’Amato, L. C., Perrone, L., Bernardi, G., & Melone, M. A. B. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.01.011 · Cited by 27
Bortvedt, S. F., McLear, J. A., Messer, A. C., Ahern‐Rindell, A. J., & Wolfgang, W. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.04.007 · Cited by 24
“In a Drosophila HD model (Steffan et al., 2001), C4-scFv decreased mutant Htt aggregation, decreased neurodegeneration, and increased lifespan (Wolfgang et al., 2005).”
BackgroundThe therapeutic potential of G-protein coupled receptors in Huntington's disease
Dowie, M. J., Scotter, E. L., Molinari, E., & Glass, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.008 · Cited by 31
Bruijn, L. I., & Cudkowicz, M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.3.417 · Cited by 30
Hannan, A. J. (2004) · Acta Biochimica Polonica · doi:10.18388/abp.2004_3581 · Cited by 24
Johnson, S. L., Tsou, W., Prifti, M. V., Harris, A. L., & Todi, S. V. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.974167 · Cited by 27
Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated BST-2/tetherin regulation
Jones, P. H., & Okeoma, C. M. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.042 · Cited by 24
Iron is a specific cofactor for distinct oxidation- and aggregation-dependent Aβ toxicity mechanisms
Ott, S., Dziadulewicz, N., & Crowther, D. C. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.019042 · Cited by 24
“We tested whether ferritin is able to suppress the rough-eye phenotypes of flies that express: (1) the dementia-linked variant of tau (tau R406W) (Wittmann et al., 2001); (2) an expanded polyglutamine polypeptide (Q48), as a model of HD; and (3) TAR DNA-binding protein 43 (TDP43), which is implicated in neurodegenerat…”
InfluentialMorphometric Analysis of Huntington’s Disease Neurodegeneration in Drosophila
Song, W., Smith, M. R., Syed, A., Lukácsovich, T., Barbaro, B. A., Purcell, J. M., Bornemann, D. J., Burke, J., & Marsh, J. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-438-8_3 · Cited by 27
Self-citationNeurotoxicity Pathways in Drosophila Models of the Polyglutamine Disorders
Krench, M., & Littleton, J. T. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.07.006 · Cited by 25
Li, S., Liu, C., Liu, C., & Zhang, Y. (2017) · Journal of Chromatography B · doi:10.1016/j.jchromb.2017.07.019 · Cited by 23
Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA)
Banno, H., Katsuno, M., Suzuki, K., Tanaka, F., & Sobue, G. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1377-9 · Cited by 26
Guide to Understanding Drosophila Models of Neurodegenerative Diseases
Jackson, G. R. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060053 · Cited by 28
“Enhancement of the polyglutamine phenotypes also was observed with an exon-1 Huntingtin construct [23], but not a larger fragment [24], indicating some importance of protein context in the interaction.”
BackgroundSelf-citationFunctional replacement of Drosophila Btk29A with human Btk in male genital development and survival
Hamada, N., Bäckesjö, C., Smith, C. I. E., & Yamamoto, D. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.06.042 · Cited by 24
“They also provide the opportunity to screen for endogenous suppressors of disease-associated phenotypes [2,14,19,26] and for exogenous substances to cure disorders [1,25].”
BackgroundHersch, S. M. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000084229.82329.03 · Cited by 23
Accelerated epigenetic aging in Huntington’s disease involves polycomb repressive complex 1
Brulé, B., Alcalá‐Vida, R., Penaud, N., Scuto, J., Mounier, C., Séguin, J., Khodaverdian, S. V., Cosquer, B., Birmelé, É., Gras, S. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56722-z · Cited by 24
Bustamante, M. B., Ansaloni, A., Falsig, J., Azzollini, L., Cariulo, C., Wang, Z.-M., Petricca, L., Verani, M., Puglisi, F., Park, H., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.116 · Cited by 26
Hat1 acetylates histone H4 and modulates the transcriptional program in Drosophila embryogenesis
Varga, J., Korbai, S., Neller, A., Zsindely, N., & Bodai, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-54497-0 · Cited by 23
Self-citationAlcalá‐Vida, R., Awada, A., Boutillier, A., & Mérienne, K. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105155 · Cited by 26
Genetic architecture of motor neuron diseases
Chaudhary, R., Agarwal, V., Rehman, M., Kaushik, A. S., & Mishra, V. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120099 · Cited by 27
Gut Microbiota as a Modifier of Huntington’s Disease Pathogenesis
Khoshnan, A. (2024) · Journal of Huntington s Disease · doi:10.3233/jhd-240012 · Cited by 24
“Notably, before the gut microbiome was identified as pathogenic modality in neurodegenerative disorders, studies showed that treatment with butyrate has protective effects in mouse and Drosophila models of HD [107, 108].”
BackgroundHui, B., Wang, W., & Li, J. (2010) · Saudi Medical Journal · doi:10.15537/1658-3175.5000 · Cited by 25
Rab11 as a modulator of synaptic transmission
Giorgini, F., & Steinert, J. R. (2013) · Communicative & Integrative Biology · doi:10.4161/cib.26807 · Cited by 21
Differential Effect of HDAC3 on Cytoplasmic and Nuclear Huntingtin Aggregates
Mano, T., Suzuki, T., Tsuji, S., & Iwata, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111277 · Cited by 24
“The up-regulation of transcription by histone deacetylase (HDAC) inhibitors was shown to be an effective treatment in a fly model of pQ disease [6].”
BackgroundLANP mediates neuritic pathology in Spinocerebellar ataxia type 1
Cvetanović, M., Kular, R. K., & Opal, P. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.07.024 · Cited by 24
Epigenetic Modifications as Novel Therapeutic Targets For Huntington’S Disease
Wang, F., Fischhaber, P. L., Guo, C., & Tang, T.-S. (2014) · Epigenomics · doi:10.2217/epi.14.19 · Cited by 25
Age-related epigenetic regulation in the brain and its role in neuronal diseases
Kim‐Ha, J., & Kim, Y.-J. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.12.184 · Cited by 24
“brains of HD patients and animal models (75, 76).”
BackgroundArabit, J. G. J., Elhaj, R., Schriner, S. E., Sevrioukov, E. A., & Jafari, M. (2018) · BioMed Research International · doi:10.1155/2018/6726874 · Cited by 28
“Male elav-Gal4 were mated with female UAS-HttQ93 to produce offspring with females expressing the extended polyQ repeat (elav-Gal4>UASHttQ93) in all nerve cells.”
BackgroundEpigenetic cerebellar diseases
Serrano, M. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64189-2.00015-9 · Cited by 22
Karuppagounder, S. S., Kumar, A., Shao, D. S., Zille, M., Bourassa, M. W., Caulfield, J. T., Alim, I., & Ratan, R. R. (2015) · Brain Research · doi:10.1016/j.brainres.2015.07.030 · Cited by 24
Kong, P., Kil, M.-O., Lee, H. J., Kim, S., Johnson, G. V. W., & Chun, W. (2008) · Neurological Research · doi:10.1179/174313208x331572 · Cited by 24
Kopito, R. R. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00498-2 · Cited by 23
Biotechnologies and therapeutics: chromatin as a target
Reik, A., Gregory, P. D., & Urnov, F. D. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00291-5 · Cited by 22
Pcaf Modulates Polyglutamine Pathology in a Drosophila Model of Huntington’s Disease
Bodai, L., Pallos, J., Thompson, L. M., & Marsh, J. (2011) · Neurodegenerative Diseases · doi:10.1159/000330505 · Cited by 21
Self-citationATXN3: a multifunctional protein involved in the polyglutamine disease spinocerebellar ataxia type 3
Hernández-Carralero, E., Quinet, G., & Freire, R. (2024) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2024.10 · Cited by 25
“CBP and p300 are transcriptional coactivators with histone acetyltransferase (HAT) activity that have important roles in transcription and have been described to be regulated by some PolyQ-containing proteins (Refs 109, 110, 111).”
BackgroundSingh, A., & Agrawal, N. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166127 · Cited by 20
Molecular biology of Huntington's disease
McFarland, K. N., & Cha, J.-H. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00003-3 · Cited by 23
Abu‐Baker, A., Laganiere, S. E., Fan, X., Laganière, J., Brais, B., & Rouleau, G. A. (2005) · Traffic · doi:10.1111/j.1600-0854.2005.00315.x · Cited by 23
“Chromatin assembly and histones are also present in the nucleus and may be involved in OPMD pathogenesis, as has been shown in poly-Q diseases (65).”
BackgroundShimohata, M., Shimohata, T., Igarashi, S., Naruse, S., & Tsuji, S. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03060.x · Cited by 22
“…that histone deacetylase inhibitors, such as trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), and sodium butyrate, decrease polyQ-induced cytotoxicities followed by a significant increase in the levels of acetylated histone H3 and H4 (McCampbell et al. 2001; Steffan et al. 2001).”
BackgroundCloning and comparative analysis of the bovine, porcine, and equine sex chromosome genesZFXandZFY
Poloumienko, A. (2004) · Genome · doi:10.1139/g03-099 · Cited by 21
Hashemian, M., Ghasemi‐Kasman, M., Parsian, H., & Sadeghi, F. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.08.014 · Cited by 24
Molecular analyses of Machado-Joseph disease
Kobayashi, T., & Kakizuka, A. (2003) · Cytogenetic and Genome Research · doi:10.1159/000072862 · Cited by 21
“…transcriptional repression mechanism has been proposed as being a potential pathological mechanism of polyQ disease, in which the histone acetyltransferase activity of coactivators, such as CBP/p300, are inhibited by direct interaction with diseased proteins (Steffan et al., 2001; Li et al., 2002).”
BackgroundThe Role of Low Complexity Regions in Protein Interaction Modes: An Illustration in Huntingtin
Kastano, K., Mier, P., & Andrade-Navarro, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041727 · Cited by 21
“For KAT2B/PCAF, a specific study found its interaction with the N-terminal (HTTex1p) domain of HTT [41].”
BackgroundChromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue
Janowski, M., Milewska, M., Zare, P., & Pękowska, A. (2021) · Pharmaceuticals · doi:10.3390/ph14080765 · Cited by 23
Smalley, J. L., Breda, C., Mason, R. P., Kooner, G. S., Luthi‐Carter, R., Gant, T. W., & Giorgini, F. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1344-5 · Cited by 21
“model of mutant HTT toxicity, in which the human exon 1encoded fragment of HTT (HTT93Q exon 1) is expressed pan-neuronally (via the elavGAL4 driver) using the bitransgenic GAL4/UAS system [36].”
MethodChoosing and usingDrosophilamodels to characterize modifiers of Huntington's disease
Green, E. W., & Giorgini, F. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120072 · Cited by 20
Gonzales, E. D., Tanenhaus, A. K., Zhang, J., Chaffee, R. P., & Yin, J. C. P. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv482 · Cited by 21
Guiretti, D., Sempere, A., López‐Atalaya, J. P., Ferrer-Montiel, A. V., Barco, Á., & Valor, L. M. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.02.004 · Cited by 26
“In the early 2000s, deficiencies in histone acetylation levels were reported in several HD models, leading to the hypothesis that this type of biochemical deficit could play a causative role in neuronal dysfunction and neurodegeneration (Steffan et al., 2001).”
BackgroundKedaigle, A. J., Reidling, J. C., Lim, R. G., Adam, M., Wu, J., Wassie, B. T., Stocksdale, J. T., Casale, M., Fraenkel, E., & Thompson, L. M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz264 · Cited by 20
Self-citationNelson, B., Nishimura, S., Kanuka, H., Kuranaga, E., Inoue, M., Hori, G., Nakahara, H., & Miura, M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401635 · Cited by 20
“In agreement with this model, both addition of histone deacetylases as well as overexpression of CBP have been shown to reduce polyQ pathology.(20,21)”
Influence of Huntington's Disease on the Human and Mouse Proteome
Zabel, C., & Klose, J. (2004) · International review of neurobiology · doi:10.1016/s0074-7742(04)61010-5 · Cited by 20
Histone acetylation regulates orphan nuclear receptor NR4A1 expression in hypercholesterolaemia
Xie, X., Song, X., Song, Y., Cai, H., Chen, Y., Chang, X., Liang, B., & Huang, D. (2015) · Clinical Science · doi:10.1042/cs20150346 · Cited by 19
Experimental Models of HD and Reflection on Therapeutic Strategies
Kim, J., Bordiuk, O. L., & Ferrante, R. J. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00016-x · Cited by 20
SUMO modulation of protein aggregation and degradation
Feligioni, M., Marcelli, S., Knock, E., Nadeem, U., Arancio, O., & Fraser, P. E. (2015) · AIMS molecular science · doi:10.3934/molsci.2015.4.382 · Cited by 19
“Drosophila PIAS protein, Su(-var)2-10 (dPIAS) has been for instance studied due to its involvement on HD-like phenotypes [151].”
BackgroundNaia, L., Ribeiro, M. J., & Rego, A. C. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.060 · Cited by 24
Auta, J., Gatta, E., Davis, J. M., Pandey, S. C., & Guidotti, A. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.416 · Cited by 20
Boutillier, A., Rouaux, C., Panteleeva, I., & Loeffler, J. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5466-1_12 · Cited by 22
“In the same study, in vitro experiments demonstrated that the Htt exon 1 protein interacted with p300/CBP Associated Factor (P/CAF) as well as p300, thereby reducing the enzymatic activity of the affected proteins (Steffan et al., 2001).”
BackgroundMethodInfluentialCalpena, E., Amo, V. L. D., Chakraborty, M., Llamusí, B., Artero, R. D., Espinós, C., & Galindo, M. I. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.029082 · Cited by 21
“To model HD inDrosophila, we used a construct for the expression of human HTT exon 1 containing expanded polyglutamine repeats (Htt-Ex1-pQ93) that has been demonstrated to induce neurodegeneration (Steffan et al., 2001).”
MethodFranich, N. R., Basso, M., André, E. A., Ochaba, J., Kumar, A., Thein, S. H., Fote, G., Kachemov, M., Lau, A., Yeung, S. Y., et al. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170274 · Cited by 20
“and is sufficient to cause neurodegeneration [58, 59], while in turn can also induce a compensatory activation of autophagy [60–63].”
BackgroundSelf-citationNguyen, H. P., Metzger, S., Holzmann, C., Koczan, D., Thiesen, H., von Hörsten, S., Rieß, O., & von Bonin, M. (2008) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800018 · Cited by 20
“Based on this, histone deacetylase (HDAC) inhibitors were initially proposed as therapeutics for HD to counteract the effects of interactions between mutant huntingtin and histone acetyl transferases, and were shown to rescue neurodegeneration and lethality in a Drosophila model of HD [3].”
Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention?
Taylor, J. P., & Fischbeck, K. H. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02332-8 · Cited by 19
From gene networks to drugs: systems pharmacology approaches for AUD
Ferguson, L. B., Harris, R. A., & Mayfield, R. D. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4855-2 · Cited by 23
Turkman, N., Liu, D., & Pirola, I. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114011 · Cited by 18
Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases
Peña‐Altamira, E., Polazzi, E., & Monti, B. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990355 · Cited by 20
Singh, V. P., Patel, K. A., Sharma, R. K., Patil, P. R., Joshi, A. S., Parihar, R., Athilingam, T., Sinha, N., Ganesh, S., Sinha, P., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00167 · Cited by 18
Expression of Human Mutant Huntingtin Protein in Drosophila Hemocytes Impairs Immune Responses
Lin, Y.-H., Maaroufi, H. O., Ibrahim, E., Kučerová, L., & Žurovec, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02405 · Cited by 20
Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets
Costa, M. D., & Maciel, P. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04280-8 · Cited by 20
Modeling Human Trinucleotide Repeat Diseases in Drosophila
Yu, Z., & Bonini, N. M. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-387003-2.00008-2 · Cited by 18
“As CBP HAT activity is thought to be inhibited by polyglutamine protein in diseases (Bodai et al., 2003; Steffan et al., 2001), these results raise the possibility that polyglutamine toxicity may also contribute to disease pathogenesis by increasing repeat stability and repeat length in cells, thereby forming a positi…”
BackgroundAdvances in the Genetics and Epigenetics of Neurodegenerative Diseases
Coppedè, F. (2013) · Epigenetics of Degenerative Diseases · doi:10.2478/end-2012-0002 · Cited by 20
Gomez, G. T., Hu, H., McCaw, E. A., & Denovan‐Wright, E. M. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.12.004 · Cited by 17
Ruetenik, A., Ocampo, A., Ruan, K., Zhu, Y., Li, C. V., Zhai, R. G., & Barrientos, A. (2016) · Microbial Cell · doi:10.15698/mic2016.08.518 · Cited by 19
Self-citationWang, Z., Hanet, A., Weishäupl, D., Martins, I., Sowa, A., Riess, O., & Schmidt, T. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12795 · Cited by 14
Ataxin2 functions via CrebA to mediate Huntingtin toxicity in circadian clock neurons
Xu, F., Kula-Eversole, E., Iwanaszko, M., Lim, C., & Allada, R. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008356 · Cited by 17
Bertrand, M., Decoville, M., Meudal, H., Birman, S., & Landon, C. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00335 · Cited by 17
Himalian, R., Singh, S. K., & Singh, M. P. (2021) · Journal of the American Nutrition Association · doi:10.1080/07315724.2021.1904305 · Cited by 21
Hou, Y., Li, J., Wu, J., Wu, Q., & Fang, J. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00023 · Cited by 17
Valproic acid neuroprotection in 6-OHDA lesioned rat, a model for parkinson's disease
Monti, B., Mercatelli, D., & Contestabile, A. (2012) · HOAJ Biology · doi:10.7243/2050-0874-1-4 · Cited by 17
“In vivo, VPA was proven neuroprotective in several animal models of acute brain damage and neurodegenerative diseases: transient cerebral ischemia in rats [17], animal models of Huntington’s disease [18,19] and Alzheimer disease [20,21], as well as in clinical trials on patients affected by spinal muscular atrophy [22…”
BackgroundZhang, Z., Teng, X., Chen, M., & Li, F. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018102 · Cited by 17
“To overcome these disadvantages, the fruitfly, Drosophila melanogaster, was widely used for modeling lots of human disorders such as neurodegenerative diseases [7–9], Huntington’s disease[10], Barth syndrome [10,11], Parkinson’s disease [12], Alzheimer’s disease [13], cancer [14], heart disease [15–17], and Multiple e…”
MethodNew Approaches to the Pathology and Genetics of Neurodegeneration
Feany, M. Β. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091077 · Cited by 19
“Pioneering work from Leslie Thompson’s group demonstrated a role for mutant huntingtin in control of histone acetylation and further showed that inhibiting histone deacetylases provided therapeutic benefit to flies expressing mutant huntingtin.(20) These findings have been replicated in vertebrate models of polyglutam…”
BackgroundTrinucleotide Repeat Disorders
Zoghbi, H. Y. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_116 · Cited by 21
Margolis, R. L. (2003) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.3.6.715 · Cited by 21
Specific N-terminal mutations in the human androgen receptor induce cytotoxicity
Funderburk, S. F., Shatkina, L., Mink, S., Weis, Q., Weg‐Remers, S., & Cato, A. C. B. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.023 · Cited by 18
Histone Deacetylase Inhibitors: Assays to Assess Effectiveness In Vitro and In Vivo
Richon, V. M., Zhou, X., Secrist, J. P., Cordon‐Cardo, C., Kelly, W. K., Drobnjak, M., & Marks, P. A. (2003) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(03)76013-3 · Cited by 17
Bates, G. P. (2001) · Nature · doi:10.1038/35099656 · Cited by 17
Choi, K., Hwang, I.-S., Park, H.-S., Oh, S., Kang, S., & Hong, S. (2014) · Biotechnology Journal · doi:10.1002/biot.201300560 · Cited by 17
Huntington’s disease: novel therapeutic perspectives hanging in the balance
Saavedra, A., Barriga, G. G.-D., Pérez‐Navarro, E., & Alberch, J. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1465930 · Cited by 18
Roles of Post-translational Modifications in Spinocerebellar Ataxias
Wan, L., Xu, K., Chen, Z., Tang, B., & Jiang, H. F. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00290 · Cited by 20
“The mutant proteins containing expanded polyQ can suppress the histone acetylase activities of some acetylation-related interactors, such as CREB-binding protein (CBP), p300 and p300/CBP-associated factor (P/CAF), through direct interaction with their acetyltransferase domains, which further inhibits histone acetylati…”
BackgroundSikder, S., Kaypee, S., & Kundu, T. K. (2020) · Journal of Biosciences · doi:10.1007/s12038-019-9974-3 · Cited by 18
Singh, M. P., Himalian, R., Shabir, S., Obaid, A. A., Alamri, A. S., Galanakis, C. M., Singh, S. K., & Vamanu, E. (2022) · Applied Sciences · doi:10.3390/app12199822 · Cited by 20
Metadata
- Authors
- Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., & Thompson, L. M.
- Affiliations
- University of California, Irvine (US)
- National Institutes of Health (US)
- Massachusetts Institute of Technology (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Thompson, Leslie M.
- ORCID
- Venue
- Nature
- Published
- 2001-10
- Volume
- 413
- Issue
- 6857
- Pages
- 739-743
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1643390591
- Cited by
- 1,228
- References
- 28
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 35 · 2020: 35 · 2019: 30 · 2018: 37 · 2017: 34 · 2016: 40 · 2015: 46 · 2014: 63 · 2013: 65 · 2012: 55
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- histone deacetylase inhibitors, polyglutamine expansion, Huntington's disease, neurodegeneration, huntingtin exon 1, CREB-binding protein, P300, PCAF, histone acetylation, histone deacetylase, Drosophila model, transcriptional dysregulation
- MeSH terms
- Huntingtin Protein, Acetylation, Acetyltransferases, Animals, Disease Models, Animal, Drosophila, Enzyme Inhibitors, Gene Expression Regulation, Glutamine, Glutathione Transferase, Histone Deacetylases, Histones, Huntington Disease, Nerve Degeneration, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Repressor Proteins, Trans-Activators, PC12 Cells, Protein Structure, Tertiary, Neurodegenerative Diseases, Repetitive Sequences, Amino Acid, Saccharomyces cerevisiae Proteins, Drosophila Proteins, Animals, Genetically Modified, E1A-Associated p300 Protein, CREB-Binding Protein, Rats, Histone Acetyltransferases, Sin3 Histone Deacetylase and Corepressor Complex, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.